Type 2 Diabetes

Study results showed that access to online information specific to the condition can increase physical activity.

You can attempt to renegotiate. Sometimes it works . . . but sometimes it doesn’t.

The sNDA is seeking an indication for the reduction of major adverse events, including cardiovascular death, myocardial infarction, and stroke.

The Certified Nurse Practicioner from the Henry Ford Medical Center also weighs in the best advice to avoid cardiovascular disease.

The Novo Nordisk product showed a greater reduction in overall blood sugar compared to the conventional insulin in clinical trials.

The extended-release GLP-1 agonist was added to usual care in T2DM patients with and without previous cardiac disease.

The FreeStyle Libre Flash Glucose Monitoring System reduces the requirement of “fingerstick” testing, with small sensor wire that continuously monitors and measures levels.

The New York University clinical professor of medicine also shared his thoughts on the future of cardiovascular disease medicine.

The Glucommander software showed patients were able to rapidly control their glucose levels and maintain their control long-term.

While previous research has shown a link between eating meat and the risk of developing type 2 diabetes, a new study is the first to evaluate the risk in people eating an eastern diet.

Gregg Fonarow, MD; David Aguilar, MD; Rob Mentz, MD; and James Januzzi, MD, discuss the unexpected and exciting use of SGLT-2 inhibitors to treat heart failure.

Rob Mentz, MD, of Duke University Medical School, discusses the CANVAS trial and the pursuit of using SGLT-2 inhibitors to treat heart failure.

Rob Mentz, MD; David Aguilar, MD; Mandeep Mehra, MD; and Lisa Rathman, MSN, discussed the use of team-based care in heart failure, a condition plagued by comorbidities and often treated by multiple specialists.

David Aguilar, MD, of Baylor College of Medicine, discusses the new responsibilities faced by cardiologists with the emerging onset of dual-indication medicines.

Patient-driven doses led to 67.5% of subjects reaching target HbA1C compared to 58.4% in the physician-driven arm.

After adjusting for comorbidities, education level, birthplace, and duration of diabetes, the data showed that men with T1D faced a slightly higher risk of AFib, but women with T1D faced a 50% higher risk of developing AFib.

The genomes associated with a higher risk of CHD are also associated with higher T2D risk, revealing the possibility of a treatment for both.

Sanofi’s dual SGLT1 and SGLT2 inhibitor was statistically significantly superior to placebo in patients with type 1 diabetes (T1D) on background insulin therapy.

A substance known as epicatechin monomers helps the body release more insulin and respond more efficiently to increased blood glucose, which could in turn benefit type 2 diabetics.

Patients in the combination arm also reached the target HbA1c level faster than those using just the single treatment therapy.

Previous guidelines indicated bypass surgery is preferable for diabetics generally, but new research sought to find out if the same held true for the relatively small number of type 1 diabetics.

At-a-Glance: Studies you may find of interest look at AFib in T1DM, new fracture risk data, obesity outcomes, and more.

Women with type 1 diabetes carry a higher risk of AFib than both men and the general public as a whole.

Five-year mortality rates decreased 7% for those who were part of the triple-screened group of the study.

The drug, produced by Sanofi, was granted approval based on the physiochemical, non-clinical, and clinical similarity to another, already approved insulin lispro injection.

In a new study, an intensive lifestyle intervention did not markedly decrease A1c but had significant impact on need for medication.

Rivaroxaban plus aspirin showed a 31% reduction in major cardiovascular events for PAD patients.

Here: 3 strategies that can help fuel the patient's drive to change.